The approval and sales of DCVax-L will certainly raise the price, hopefully sufficiently for either a Nasdaq or NYSE application. I've heard that there is a course of action they could take to get on the Nasdaq below $4 because they were previously listed, but I've also heard that LP really wants the NYSE. We definitely have to get on a major exchange before we can get the sort of market cap, or buyout, we want.
I believe that a compromise, if they wish to take it, is the AMEX. I understand that you can file for that at a price above $1 which should be easy to reach after the initial approval.
Frankly the exchanges, who use stock price, and not market cap, to determine who can list, are largely forcing many companies to do reverse splits which almost always diminish market cap, at least initially. I respect the company for reaching a major exchange the right way, buy building the stock price. I really believe the exchanges ought to use market cap, not share price, to determine listing eligibility. NWBO has a far greater market cap than many stocks on the major exchanges. I understand that year's ago NWBO did reverse splits, they've learned from that and don't want to do it again.
Success with a high share count is certainly not a problem, look at ABBV which just bought out IMGN and another company for billions, it currently has over 1.7 billion shares outstanding. If NWBO remained independent and had tumor agnostic labels for both DCVax's I don't know that they couldn't have a market cap as large as ABBV's, nearly $300 billion, in fact I still believe a trillion market cap possible if our vaccines are being used for practically every patient with a solid cancer.
Gary
Market Data 
Markets 
AI
